



			NGS		Cohen's κ
			Detected	Not Detected	
G-banding karyotyping	CBF fusion transcript	Detected	16	2	0.90
		Not Detected	1	146	
	KMT2A-rearrangement	Detected	8	1	0.83
		Not Detected	2	154	
	Total	Detected	24	3	0.87
		Not Detected	3	135	

The fusion genes used in the evaluation are as follows,  
 CBF fusion transcript, t(8;21)(q22;q22.1);RUNX1-RUNX1, inv(16)(p13.1;q22) or t(16;16)(p13.1;q22);CBFB-MYH11  
 KMT2A-rearrangement, t(9;11)(p21.3;q23.3);KMT2A-MLLT3, t(11;19)(q23;q13.1);KMT2A-MLLT1, t(10;11)(p12;q23);KMT2A-MLLT10, t(1;11)(q21;q23);KMT2A-MLLT11, t(6;11)(q27;q23);KMT2A-MLLT4, t(X;11)(q13;q23);KMT2A-SEPT6 t(11;17)(11;17);KMT2A-SEPT9





Chromosome	11	1	6	9	10	17	19	X	11
Gene	<i>KMT2A</i>	AF1Q	AF6	AF9	AF10	SEPT9	ENL	SEPT6	Partial Tandem Duplication
Patients (% of all participants)		1 (0.6%)	2 (1.1%)	3 (1.7%)	1 (0.6%)	1 (0.6%)	1 (0.6%)	1 (0.6%)	10 (5.6%)



Chromosome	11	5	7	7
Gene	<i>NUP98</i>	NSD1	TNRC18	HOXA9
Patients (% of all participants)		1 (0.6%)	1 (0.6%)	3 (1.7%)

Red arrows indicate the site of translocation.





Supplement Fig. 7 Schematic overview of mutation sites of *WT1* in the analysis cohort.

